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MEG3 is associated with poor prognosis
and promoter hypermethylation
in cervical cancer
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Abstract
Background: Our previous study reported that MEG3 is an important tumor suppressor gene that is inactivated in
cervical cancer. However, the diagnostic and prognostic values of MEG3, as well as the molecular mechanism of
MEG3 inactivation in cervical cancer, remain unclear. In this study, we aimed to further elucidate the role and
potential inactivation mechanism of MEG3 in cervical cancer.
Methods: ROC curve and Cox regression analyses were used to assess the diagnostic and prognostic value of
MEG3 in patients with cervical cancer. The methylation status of the MEG3 promoter in cervical cancer tissue
samples was tested using methylation-specific PCR. Furthermore, we altered the methylation status of the MEG3
promoter in two cervical cancer cell lines (HeLa and CaSki) using a DNA methylation transfer enzyme inhibitor
(5-Aza-CdR), to investigate whether promoter hypermethylation is a potential cause of MEG3 inactivation. Finally,
we used CCK-8 and colony formation assays to evaluate the cell proliferation ability of HeLa and CaSki cells that
had been treated with 5-aza-CdR, to investigate whether downregulation of MEG3 caused by promoter
hypermethylation had biological effects.
Results: ROC curve analysis indicated that MEG3 status showed sufficient sensitivity and specificity for prediction of
tumor size and lymph node metastasis in patients with cervical cancer. In addition, our follow-up data showed that
low MEG3 expression was correlated with recurrence and short overall survival. Moreover, hypermethylation of the
MEG3 promoter was observed in most cervical cancer tissue samples, and demethylation of the MEG3 promoter led
to re-expression of MEG3 and inhibited proliferation of HeLa and CaSki cells.
Conclusions: MEG3 is a powerful tool for diagnosis and prognosis of patients with cervical cancer, and low
expression of MEG3 is likely to be related to promoter hypermethylation in cervical cancer.
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Background
Cervical cancer is one of the most commonly diagnosed
cancers among women worldwide, accounting for over
500,000 new cases and 260,000 cases of death annually
[1]. Although the incidence and mortality rates of
cervical cancer have declined over the past 30 years, the
5-year survival rate of advanced-stage patients has
remained below 40% [2, 3]. Therefore, it is important to
explore the molecular mechanisms of cervical cancer in
order to identify effective prognostic markers and design
improved therapeutic strategies.
Long noncoding RNA (lncRNA) is usually defined as
an RNA molecule that is longer than 200 nucleotides
and lacks significant protein-coding capacity [4]. Studies
have reported that lncRNAs regulate various biological
processes such as gene expression, transcription, and
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cellular proliferation, among others [5, 6]. More import-
antly, abnormal expression of lncRNAs was also found
to be involved in metastasis, recurrence, and prognosis
of various human cancers [7]. Maternally expressed gene
3 (MEG3), a lncRNA that has attracted much research
interest, is aberrantly expressed in several human cancers
including gastric cancer [8, 9], colorectal cancer [10],
retinoblastoma [11], and ovarian cancer [12] according to
recent studies. Moreover, our previous study showed that
MEG3 is associated with the progression of cervical can-
cer via regulation of cell proliferation and apoptosis [13].
However, the diagnostic and prognostic value of MEG3
for cervical cancer remains unknown.
In addition to inducing abnormal expression of tumor
suppressor genes and oncogenes, epigenetic alterations
play an important role in the development of cancers.
Many studies have confirmed that hypermethylation of
gene promoter regions can directly cause a decrease in
gene expression levels [14]. Hypermethylation of the
promoter region of tumor suppressor genes, including
genes that encode lncRNAs, is a common cause of
cancer [15]. However, no reports have been published to
date on the relationship between promoter methylation
and MEG3 expression in cervical cancer.
In this study, we investigated the relationship between
MEG3 and cervical cancer based on the results of our
previous study. We first performed ROC curve and Cox
regression analyses to determine the clinical value of
MEG3 in patients with cervical cancer. Then we identi-
fied the epigenetic regulation of MEG3 expression in
cervical cancer tissues and cells. These results deepen




Seventy-two cervical cancer tissue and its corresponding
normal tissues were obtained from patients admitted to
our hospital for surgery from April 2012 to March 2013.
The specimens were immediately placed in liquid nitrogen
after surgical resection. All the patients were newly diag-
nosed as cervical cancer without receiving any treatment.
The samples which considered as cervical cancer or nor-
mal tissues were determined by pathologic examination.
Written consent was obtained from each patient before
tissue collection. The protocol was approved by the Insti-
tutional Research Ethics Committee of our hospital. The
patients’ clinico-pathological characteristics are summa-
rized in Additional file 1: Table S1.
Cell lines and culture
Cervical cancer cell lines HeLa and CaSki were
purchased from the Institute of Biochemistry and Cell
Biology at the Chinese Academy of Sciences (Shanghai,
China). HeLa cells were maintained in DMEM (Gibco,
Gaithersburg, MD, USA) supplemented with 10% fetal
bovine serum (FBS, Gibco) and CaSki cells were
cultured in RPMI 1640 medium (Gibco) with 10% FBS
at 37 °C in a humidified incubator of 5% CO2.
Transfection of siRNA
SiRNA for this study was the same as our previous study.
Briefly, the siRNA for knockdown MEG3 (si-MEG3) and
its negative control (si-NC) were designed and synthesized
by GenePharma (Shanghai, China). SiRNA was trans-
fected using Lipofectamine 2000 (Invitrogen, Carlsbad,
California, USA) according to the manufacturer’s
protocol. 48 h after transfection, cells were harvested
and subjected to qRT-PCR analyses and functional
assays.
RNA isolation and qRT-PCR
Total RNA was isolated from tissues and cells using
Trizol reagent (TaKaRa, Otsu, Japan) according to the
manufacturer’s instructions. Concentration and purifica-
tion of RNA were determined by measuring its optical
density using NanoDrop 2000 Spectrophotometer (1.8 <
A260/280 < 2.0, Thermo Scientific Wilmington, DE,
USA). Reverse transcription was carried out using
PrimeScriptTM RT reagent Kit following the manufac-
turer’s protocol (TaKaRa). QRT-PCR was performed
using a SYBR Premix Ex Taq II kit (TaKaRa). Briefly,
reactions were loaded into a 96-well plate in duplicate
and firstly incubated at 95 °C for 5 min, followed by
40 cycles of denaturation at 95 °C for 30 s, 1 min of
annealing at 60 °C and extension at 60 °C for 1 min on
CFX96 Real-Time PCR Detection System (Bio-Rad,
Hercules, California, US). The β-Actin was chosen as
the endogenous normalizer and the 2−ΔΔCt method was
used to determine relative expression of MEG3. The
primers used for qRT-PCR in this study are the same as
our previous study.
Methylation specific PCR for promoter of MEG3
First, DNA from cells and tissues was extracted using
the QIAmp DNA Mini kit (Qiagen, German), according
to the manufacturer’s recommendations. Next, we used
the EpiTect Bisulfite kit (Qiagen) for bisulfate conver-
sion following the product manual. At last, Methylation
specific PCR (MSP) was performed on Bisulfite-treated
DNA using EpiTect MSP kit (Qiagen). The primers of
MEG3 promoter which specific for methylated and
unmethylated were as follows: the methylated pair (M)
was 5′-GTT AGT AAT CGG GTT TGT CGG C (for-
ward) and 5′-AAT CAT AAC TCC GAA CAC CCG CG
(reverse); the unmethylated pair (U) was 5′-GAG GAT
GGT TAG TTA TTG GGG T (forward) and 5′-CCA
CCA TAA CCA ACA CCC TAT AAT CAC A (reverse).
Zhang et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:5 Page 2 of 9
The PCR reaction was conducted in DNA Engine Tetrad
2 Peltier Thermal Cycler (Bio-Rad) under the following
conditions: 95 °C 15 min; 94 °C 30s, 70 °C 30s, 72 °C
30s, 5 cycles; 94 °C 30s, 65 °C 30s, 72 °C 30s, 5 cycles;
94 °C 30s, 60 °C 30s, 72 °C 30s, 30 cycles; 72 °C 7 min.
The PCR products were identified by electrophoresis
through 2.5% agarose gel, stained with ethidium brom-
ide, visualized under UV and compared by densitometry.
Treatment with 5-Aza-CdR and DZNep
The DNA demethylating agent 5-aza-2-deoxy-cytidine
(5-Aza-CdR) was obtained from Sigma-Aldrich (MO,
USA) and diluted in dimethyl sulfoxide (DMSO, MP
Biomedicals, California, USA). Total 1 × 105 cells were
seeded in six-well culture plate and treated with 0, 5,
10 μmol/L 5-aza-CdR for next 5 days. The medium was
replaced with the same concentration of 5-Aza-CdR
every day. Then cells were collected and prepared for
qRT-PCR and MSP to measure the expression of MEG3
and the methylation status of the MEG3 promoter
respectively. For CCK-8 assay, we treated cells with
10 μmol/L 5-aza-CdR for 5 days, following transfection
of si-MEG3 and compared proliferation ability with cells
which were treated with 5-Aza-CdR only.
3-Deazaneplanocin A (DZNep), an inhibitor of the
histone methyltransferase EZH2, was purchased from
Sigma-Aldrich (MO, USA). The cells were seeded at 1 ×
105 cells per well and treated with DZNep at 0, 1 and
5 μmol/L for 5 days. After that, cells were harvested for
qRT-PCR and Western Blot.
CCK-8 assay
Cell proliferation ability was evaluated using Cell Count-
ing Kit-8 (CCK-8, Dojindo, Kumamoto, Japan) following
the manufacturer’s instructions. Briefly, Hela and Caski
cells were harvested 48 h post-transfection before seeding
into a 96-well plate at a density of 3x103 cells per well.
After 6 h of incubation, 10 μl CCK-8 was added to each
well at 0, 24, 48 or 72 h time point. Cells were incubated
for 1.5 h at 37 °C and the absorbance was read at 450 nm
using SoftMax pro5 Microplate Reader (Molecular
Devices, California, USA).
Colony formation assay
For Colony formation assay, 1x103 cells per well were
seeded into the 6-well plates and cultured for 7 days in
complete growth media. Afterwards, the adherent cells
were washed with PBS, fixed with 10% paraformaldehyde
for 10 min, stained with 1% Crystal violet for 5 min,
photographed and counted.
Western blot
The cells were lysed with RIPA (Thermo Scientific,
USA) supplemented with protease inhibitors (Roche,
Switzerland) according to the manufactures protocol.
Fifty micrograms of proteins were separated by SDS-
PAGE and transferred to PVDF membranes (Roche,
Switzerland). Afterwards, the membranes were blocked
and incubated with rabbit anti-human EZH2 antibody
(1:1,000; CST, USA) at 4 °C overnight. Then mem-
branes were washed with TBST and probed with HRP
Goat-anti-Rabbit (1:2000; Santa Cruz Biotechnology)
at room temperature for 2 h. At last, the proteins were
measured semiquantitatively with ECL (Thermo Scientific)
and normalized to the expression of β-Actin (1:1,000; CST,
USA).
Statistical analysis
Each experiment was performed in triplicate and the
results were represented as mean ± SEM. The SPSS
software (version 11.0, SPSS Inc, USA) was used for the
statistical analyses. Differences between groups were
compared using the Student’s t test or LSD test for
continuous variables and the Pearson’s chi-square test for
qualitative variables. Statistical significance was considered
at P ≤ 0.05.
Results
Diagnostic value of MEG3 for patients with cervical cancer
The results of qRT-PCR analysis showed that MEG3
expression was significantly lower in cervical cancer
tissues compared to corresponding normal tissues,
consistent with our previous study (Fig. 1a). Because
MEG3 was shown to be significantly associated with
tumor size and lymph node metastasis in our previ-
ous study, we conducted receiver operating character-
istic (ROC) curve analysis to test its diagnostic value.
The results showed that MEG3 could be a candidate
to discriminate between tumors < 4 cm and tumors ≥
4 cm, with an AUC (area under the ROC curve) of
0.745, a sensitivity of 56.1%, and a specificity of 80.6%
at a cut-off value of 0.705 (P < 0.001, Fig. 1b). ROC
curve analysis also revealed that MEG3 could serve as
a biomarker for lymph node metastasis, with an AUC
of 0.716. At a cut-off value of 0.475, the sensitivity
and the specificity were 70.5% and 67.9%, respectively
(P = 0.002, Fig. 1c).
In addition, we tested the ROC model above using
data collected from 108 patients with cervical cancer in
our previous study. The AUCs for tumor size and
lymph node metastasis were 0.753 and 0.862, respectively
(P < 0.001, Fig. 2). Furthermore, at a cut-off value of 0.705,
the sensitivity and specificity for diagnosis of tumor size
(<4 cm or ≥ 4 cm) were 54.8% and 84.8%, respectively
(Fig. 2a). When the cut-off value was 0.475, the sensitivity
and specificity for prediction of lymph node metastasis
were 76.1% and 85.4%, respectively (Fig. 2b).
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Relationship between MEG3 expression and prognosis
To further evaluate whether MEG3 expression is linked
to survival, patients with cervical cancer (n = 72) were
classified into the MEG3-Low (n = 36) and MEG3-High
groups (n = 36) according to the median value of MEG3
expression. Kaplan–Meier analysis showed that patients
in the MEG3-Low group had significantly shorter
recurrence-free and overall survival than those in the
MEG3-High group (P < 0.01, Fig. 1d, e).
Furthermore, we tested the predictive value of MEG3
for relevant clinical and pathological parameters, including
tumor size, FIGO stage, lymph node metastasis, HR-HPV
infection, age, menopause, histology, depth of invasion, dif-
ferentiation, and lymphatic vascular space invasion (LVSI).
Univariate analysis showed that MEG3 expression, differ-
entiation, FIGO stage, and lymph node metastasis were all
prognostic factors for recurrence-free survival in patients
with cervical cancer (Table 1). In a multivariate analysis
based on the Cox proportional hazards regression model,
only MEG3 expression, FIGO stage, and lymph node
metastasis were found to be independent prognostic
markers for recurrence-free survival (Table 1).
Methylation status of the MEG3 promoter in cervical
cancer tissues
The methylation status of the MEG3 promoter was
assessed by MSP. The unmethylated pattern (U), partially
methylated pattern (M and U), and methylated pattern
Fig. 1 The diagnostic and prognostic value of MEG3 in cervical cancer. a Relative expression of MEG3 in cervical cancer tissues (n = 72) and
corresponding normal tissues (n = 72). ROC curve of MEG3 expression predicts the tumor size (b) and presence of lymph nodes metastasis (c) in
terms of sensitivity and specificity. d, e Patients in MEG3-Low group (n = 36) had significantly shorter recurrence-free and overall survival than
those in MEG3-High group (n = 36). P value was calculated by Log-rank test.**P < 0.01
Fig. 2 MEG3 cut-off values for tumor size (a) and presence of lymph nodes metastasis (b) setting before were tested by other 108 patients with
cervical cancer from our previous study. The AUC was 0.753 (P < 0.001, a) and 0.862 (P < 0.001, b), respectively
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(M) were observed in 12.5%, 22.2%, and 65.3% of cervical
cancer tissues, respectively. In comparison, the
unmethylated pattern (70.8%) was more common than
the methylated (13.9%) or partially methylated
patterns (15.3%) in corresponding normal tissues
(Fig. 3a, Table 2). The difference in promoter methy-
lation status between cervical cancer tissues and cor-
responding normal tissues was statistically significant
(P < 0.001, Table 2). More importantly, there was a
positive correlation between cervical cancer and promoter
hypermethylation (R = 0.592, Table 2). MEG3 methylation
was a risk factor for cervical cancer (OR = 17, Table 2).
To better understand the role of methylation, we also
analyzed the correlation between MEG3 expression and
promoter methylation level in cervical cancer tissues. As
shown in Fig. 3b, expression of MEG3 was significantly
higher in the unmethylated group than in the methyl-
ated or partially methylated groups.
Table 1 Univariate and Multivariate analyses for recurrence-free survival
Risk factors Univariate analysis Multivariate analysis
HR P value 95% CI HR P value 95% CI
MEG3 expression 0.111 0.002 0.027 ∼ 0.451 0.159 0.040 0.028 ∼ 0.919
FIGO stage, (I, II) 3.687 <0.001 1.780 ∼ 7.634 3.033 0.005 1.400 ∼ 6.571
Lymph nodes metastasis (Negative, Positive) 2.095 0.043 1.023 ∼ 4.291 2.259 0.048 1.007 ∼ 5.070
Differentiation (Well/Moderately, Poorly) 2.134 0.040 1.036 ∼ 4.396 0.670 0.406 0.201 ∼ 1.722
Depth of invasion (≤2/3, >2/3) 1.358 0.403 0.663 ∼ 2.783
HR HPV infection (Negative, Positive) 1.501 0.347 0.643 ∼ 3.502
Tumor size 1.243 0.132 0.936 ∼ 1.652
LVSI (Negative, Positive) 0.797 0.538 0.387 ∼ 1.643
Age 0.998 0.894 0.967 ∼ 1.030
Histology (Squamous, Adenocarcinoma) 0.927 0.961 0.412 ∼ 2.240
Menopause (Yes, No) 1.426 0.333 0.696 ∼ 2.921
HR hazard ratio
Fig. 3 Methylation status of the MEG3 promoter in cervival cancer. a Methylation status of MEG3 promoter in cervival cancer tissues (C1-C5 as
example) and its corresponding normal tissues (N1-N5 as example) was tested by MSP. The methylated pattern (M) of MEG3 was 160 bp and the
unmethylated pattern (U) was 120 bp. b Patients were classified into methylation group (M), partially methylated group (MU) and unmethylated
group (U) based on the methylation levels of MEG3 promoter. MEG3 expression level was associated with the methylation level of MEG3
promoter. c Hypermethylation of MEG3 promoter indicated poor recurrence-free survival. *P < 0.05, **P < 0.01
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Furthermore, HR-HPV infection and lymph node
metastasis were significantly correlated with MEG3
methylation (Table 3). The Chi-square test also indicated
that MEG3 methylation was a risk factor for HR-HPV
infection and lymph node metastasis (Table 3). However,
MEG3 methylation was not significantly correlated with
age, menopause, histology, differentiation, FIGO stage,
tumor size, depth of invasion, or LVSI in cervical cancer
(Table 3). Moreover, Kaplan–Meier analysis showed that
the promoter methylation level of MEG3 was signifi-
cantly correlated with recurrence-free survival time:
patients in the methylated group had significantly
shorter recurrence-free survival times than those in the
partially methylated or unmethylated groups (P = 0.015,
Fig. 3c).
Epigenetic regulation of MEG3 in cervical cancer cells
As the MSP assay showed, the promoter of MEG3 was
hypermethylated in HeLa and CaSki cells (0 μmol/L,
Fig. 4a). To investigate the role of promoter methylation
in regulation of MEG3 expression in cervical cancer
cells, we examined the effect of 5-aza-CdR on promoter
methylation levels and MEG3 expression. Compared
with the control treatment, 5-aza-CdR treatment signifi-
cantly decreased the promoter methylation level in HeLa
and CaSki cells (Fig. 4a). Furthermore, qRT-PCR analysis
indicated that expression of MEG3 was significantly
higher in the 5-aza-CdR treatment group than in the
control group (Fig. 4b, P < 0.05).
In addition, we also examined the effects of DZNep
treatment based on HeLa and CaSki cells. We first
confirmed the significant reduction of EZH2 protein
levels (Fig. 4c). However, no significant change in MEG3
expression levels was observed after treatment with
DZNep (Fig. 4d).
Methylation status of the MEG3 promoter influenced
proliferation of cervical cancer cells
As shown by the CCK-8 assay, 5-aza-CdR significantly
decreased the proliferation ability of HeLa and CaSki
cells, compared with control cells (Fig. 5a, P < 0.05).
According to the colony formation assay, 5-Aza-CdR
(10 μmol/L 5-Aza-CdR + si-NC group) also resulted in a
notable decrease in the number of colonies, as compared
with the control groups (0 μmol/L 5-Aza-CdR + si-NC
group) (Fig. 5d P < 0.05). To prevent excessive use of si-
MEG3, qRT-PCR confirmed that there was no significant
difference in MEG3 expression between the 5-aza-CdR
(10 μmol/L) + si-MEG3 and the si-NC groups (Fig. 5b).
The efficiency of si-MEG3 was tested in our previous
study. Furthermore, the CCK-8 and colony formation
assays indicated that the proliferation ability of HeLa
and CaSki cells in the 5-aza-CdR (10 μmol/L) + si-MEG3
group was significantly higher than that in the 5-aza-
CdR (10 μmol/L) + si-NC group (Fig. 5c, d, P < 0.05).
Discussion
Our previous study showed that MEG3 expression levels
are related to HR-HPV infection, tumor size, FIGO
stage, and lymph node metastasis in patients with cer-
vical cancer [13]. However, the value of MEG3 in clinical
practice is generally unknown. In the present study, we
identified MEG3 as a potential marker for lymph node
metastasis. Then we tested the ROC model using data
from 108 other patients with cervical cancer from our
previous study. The results confirmed that the MEG3
expression cut-off value that we set previously for
prediction of lymph node metastasis was still effective,
supporting our previous results. The presence or
absence of lymph node metastasis is a crucial factor in
therapy decision-making for patients with cervical can-
cer and our study found that MEG3 is a good candidate
to predict it. That indicates that MEG3 shows excellent
potential value for clinical work, especially for cervical
cancer, in which biopsy is routine before therapy.
The lack of valid prognostic prediction models makes
it difficult to apply individualized therapy to patients with
cervical cancer. Developing a method for identifying
patients at high risk of treatment failure is important. For
these high-risk patients, modified therapies such as neoad-
juvant radiation or chemotherapy could potentially be
Table 2 Correlation between cervical cancer and methylation
status of MEG3 promoter




63 9 50.4 <0.001 0.592 17.000 (7.167–40.324)
Normal 21 51
OR odds ratio
Table 3 Relationship between MEG3 methylation and clinical
pathological characteristics in patients with cervical cancer
Clinical pathological characteristics P R OR (95% CI)
HR HPV infection (Positive, Negative) 0.013 0.291 3.830
(1.279–11.467)
Lymph nodes metastasis (Positive, Negative) 0.025 0.264 3.520
(1.131–10.953)
FIGO stage (II, I) 0.056
Depth of invasion (>2/3, ≤2/3) 0.106
Differentiation (Well/Moderately, Poorly) 0.741
Tumor size (>4 cm, ≤4 cm) 0.703
LVSI (Positive, Negative) 0.675
Age (>50, ≤50) 0.371
Histology (Squamous, Adenocarcinoma) 0.899
Menopause (Yes, No) 0.658
OR odds ratio
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applied to improve patient survival. Although extensive
effort has been devoted to understanding the prognostic
value of MEG3 in human tumors [8, 10, 11], little was
known about its value in cervical cancer until now. In the
present study, we evaluated the prognostic value of MEG3
using Kaplan–Meier and Cox regression analyses.
Kaplan–Meier analysis of patients with cervical cancer
indicated that MEG3 expression level was associated with
recurrence-free and overall survival. Furthermore, MEG3
was confirmed to be an independent prognostic marker
for recurrence-free survival by multivariate analysis.
Therefore, MEG3 may represent a novel indicator of
prognosis in cervical cancer, helping to identify high-risk
patients before treatment.
Emerging results indicate that epigenetic aberrations,
especially DNA methylation, regulate tumor growth by
silencing tumor suppressor genes [16, 17]. The promoter
region as well as the intergenic germ line-derived differ-
entially methylated region (IG-DMR) of MEG3 is rich in
CpG dinucleotides [18]. Thus, many studies have re-
ported that promoter methylation plays an important
role in loss of MEG3 expression in tumors [8, 11, 19]. In
this study, we tested the hypothesis that promoter
hypermethylation may be able to reduce MEG3 levels in
cervical cancer, by evaluating the methylation level of
the MEG3 promoter and its effects on MEG3 expression.
Similar to other findings, low MEG3 expression was
shown to be related to hypermethylation of the MEG3
promoter in cervical cancer tissues.
Further, we endeavored to reveal the role of MEG3
methylation in the progress of cervical cancer. We found
that MEG3 methylation is not only a risk factor for
cervical cancer, but also for HR-HPV infection and
lymph node metastasis. More importantly, patients with
hypermethylation of the MEG3 promoter showed poor
recurrence-free survival. Collectively, these results indi-
cate the importance of MEG3 methylation in cervical
cancer progression. Interestingly, we noted that the role
of MEG3 methylation was consistent with that of MEG3
expression in cervical cancer, and the clinical character-
istics of patients in the methylated group were similar to
those of patients in the MEG3-Low group, according to
our previous study. These results provide strong
evidence for the relevance of MEG3 inactivation and
promoter hypermethylation.
In addition, we showed, using cell-based experiments,
that promoter methylation and MEG3 expression are
correlated. We revealed that the MEG3 promoter is
hypermethylated in cervical cancer cells, and that
demethylation of the promoter resulted in re-expression
Fig. 4 The effects of 5-aza-CdR and DZNeP on MEG3 expression. a MEG3 promoter was hypermethylation in HeLa and CaSki cells (0 μmol/L).
MEG3 promoter could be demethylation by different concentrations of 5-aza-CdR (5 and 10 μmol/L) in HeLa and CaSki cells. b MEG3 was
re-expressed in the HeLa and CaSki cells treated with different concentrations of 5-aza-CdR (5 and 10 μmol/L), compared to cells of the control
group (0 μmol/L 5-aza-CdR). c EZH2 protein levels in cells treated with DZNep (0, 5 μmol/L) were examined by western blot d MEG3 expression was
analyzed by RT-qPCR in cells treated with DZNep (0, 1, 5 μmol/L) for 5 days and there was no significant statistical difference among the groups
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of MEG3. More importantly, as the promoter methyla-
tion level decreased, the expression of MEG3 increased
in cervical cancer cells, which indicated that loss of
MEG3 expression in cervical cancer cells was the result
of promoter hypermethylation, at least in part. More-
over, our results indicated that a decrease in the methy-
lation level resulted in not only re-expression of MEG3,
but also reduction of the proliferation potential in
cervical cancer cells. Furthermore, repression of MEG3
re-expression could partly reverse the inhibitory effect of
5-aza-CdR on proliferation of HeLa and CaSki cells,
revealing that MEG3 re-expression may play a crucial role
in 5-aza-CdR functions. Based on the above results, we
have a clear indication that MEG3 re-expression owing to
DNA demethylation could inhibit proliferation of cervical
cancer cells. The results also indicate that inactivation of
MEG3 via promoter hypermethylation plays an important
role in regulation of cervical cancer cell proliferation. In
addition, it confirms the results of our previous study, that
down-regulation of MEG3 could suppress the prolifera-
tion of cervical cancer cells in another way. In summary,
we propose that the following process may occur in
cervical cancer cells: promoter hypermethylation→ inacti-
vation ofMEG3→malignant cell proliferation.
In addition to DNA methylation, we are also interested
in the effect of histone methylation on MEG3 expression.
DZNep has been shown to reduce expression of EZH2,
inhibit methylation of H3K27, and affect histone methyla-
tion [20]. However, DZNep did not significantly affect
MEG3 expression in cervical cancer cells, implying that
histone methylation may not be a major mechanism of
MEG3 inactivation. However, this is just the first step in
study of histone methylation of MEG3 and much remains
to be done.
Fig. 5 The effects of 5-aza-CdR on cervical cancer cells proliferation in vitro. a 5-aza-CdR dramatically decreased the proliferation ability of HeLa
and CaSki cells by CCK-8 assay. b si-MEG3 was just canceled out the promoting effect of 5-aza-CdR on MEG3 expression. c and d si-MEG3 could partly
reverse the inhibitory effect of 5-aza-CdR on proliferation of HeLa and CaSki cells, as shown by CCK-8 assays and Colony formation assays. *P < 0.05
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Conclusions
MEG3 may be a useful diagnostic tool and prognostic
marker for cervical cancer, and its inactivation in
cervical cancer may be due to promoter hypermethy-
lation. MEG3 shows potential for use in diagnostic
applications and therapeutic interventions in cervical
cancer.
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(DOC 40 kb)
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